ID

38595

Description

Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form contains information on the Randomisation of trial participants as well as the actual application of the investigational product GSK1995057 on Day 1.

Link

https://clinicaltrials.gov/ct2/show/NCT01476046

Keywords

  1. 10/25/19 10/25/19 -
Copyright Holder

GlaxoSmithKline

Uploaded on

October 25, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Phase I Trial of Intravenous TNFR1 Antagonist GSK1995057 in Healthy Subjects - NCT01476046

Randomisation and Investigational Product - IV Dosing

Administrative data
Description

Administrative data

Alias
UMLS CUI-1
C1320722
Subject Number
Description

Subject Number

Data type

integer

Alias
UMLS CUI [1]
C2348585
Date/Time of Assessment
Description

Date/Time of Assessment

Data type

datetime

Alias
UMLS CUI [1,1]
C2985720
UMLS CUI [1,2]
C1264639
Cohort
Description

Cohort

Data type

text

Alias
UMLS CUI [1]
C0599755
Randomisation Number
Description

Randomisation Number

Alias
UMLS CUI-1
C0034656
UMLS CUI-2
C0237753
Was the subject able to be randomised?
Description

If yes, provide Randomisation Number and Date/time of randomisation

Data type

boolean

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C0332149
Randomisation Number
Description

if applicable

Data type

integer

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C0237753
Date/time of randomisation
Description

if applicable

Data type

datetime

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C1264639
Investigational Product - IV dosing
Description

Investigational Product - IV dosing

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0678766
UMLS CUI-3
C0348016
Start Date and Time
Description

Time is optional

Data type

partialDatetime

Alias
UMLS CUI [1,1]
C3897500
UMLS CUI [1,2]
C3469597
UMLS CUI [1,3]
C0304229
Stop Date and Time
Description

Time is optional

Data type

partialDatetime

Alias
UMLS CUI [1,1]
C3899266
UMLS CUI [1,2]
C3469597
UMLS CUI [1,3]
C0304229
Total dose given
Description

Dose of investigational product

Data type

float

Measurement units
  • mg
Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0678766
mg
Units
Description

[hidden]

Data type

text

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0678766
UMLS CUI [1,3]
C1519795
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
Description

If no, record reasons. Per Protocol treatment: 0.0004 mg/kg (Cohort 1), 0.002 mg/kg (Cohort 2), 0.01 mg/kg (Cohort 3), 0.05 mg/kg (Cohort 4), 0.25 mg/kg (Cohort 5), 2.0 mg/kg (Cohort 6/7), administered over 1 hour (Cohort 1), 2 hours (Cohort 2) or 3 hours (Cohorts 3 to 7).

Data type

text

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C2349182
Record reason(s)
Description

if applicable

Data type

text

Alias
UMLS CUI [1,1]
C0566251
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C3827420

Similar models

Randomisation and Investigational Product - IV Dosing

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative data
C1320722 (UMLS CUI-1)
Subject Number
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
Date/Time of Assessment
Item
Date/Time of Assessment
datetime
C2985720 (UMLS CUI [1,1])
C1264639 (UMLS CUI [1,2])
Item
Cohort
text
C0599755 (UMLS CUI [1])
Code List
Cohort
CL Item
Part A Cohort 1 (A)
CL Item
Part A Cohort 2 (B)
CL Item
Part A Cohort 3 (C)
CL Item
Part B Cohort 4 (D)
CL Item
Part B Cohort 5 (E)
CL Item
Part B Cohort 6 (F)
CL Item
Part B Cohort 7 (open label) (G)
Item Group
Randomisation Number
C0034656 (UMLS CUI-1)
C0237753 (UMLS CUI-2)
Randomisation possible
Item
Was the subject able to be randomised?
boolean
C0034656 (UMLS CUI [1,1])
C0332149 (UMLS CUI [1,2])
Randomisation Number
Item
Randomisation Number
integer
C0034656 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
Randomisation Date/Time
Item
Date/time of randomisation
datetime
C0034656 (UMLS CUI [1,1])
C1264639 (UMLS CUI [1,2])
Item Group
Investigational Product - IV dosing
C0304229 (UMLS CUI-1)
C0678766 (UMLS CUI-2)
C0348016 (UMLS CUI-3)
Start Date/Time Investigational Product Administration
Item
Start Date and Time
partialDatetime
C3897500 (UMLS CUI [1,1])
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Stop Date/Time Investigational Product Administration
Item
Stop Date and Time
partialDatetime
C3899266 (UMLS CUI [1,1])
C3469597 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Dose of investigational product
Item
Total dose given
float
C0304229 (UMLS CUI [1,1])
C0678766 (UMLS CUI [1,2])
Item
Units
text
C0304229 (UMLS CUI [1,1])
C0678766 (UMLS CUI [1,2])
C1519795 (UMLS CUI [1,3])
CL Item
Litre  (L)
CL Item
Millilitre (ML)
CL Item
Microlitre (MCL)
CL Item
Gram (G)
CL Item
Milligram (MG)
CL Item
Microgram (UG) (UG)
Item
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
text
C0087111 (UMLS CUI [1,1])
C2349182 (UMLS CUI [1,2])
Code List
Did the subject receive the correct treatment (e.g., treatment which the subject was assigned to) during this dosing interval?
CL Item
Yes (Y)
CL Item
No (N)
Reason incorrect treatment
Item
Record reason(s)
text
C0566251 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C3827420 (UMLS CUI [1,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial